Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 2/20 | 0.54 |
| ▸ | MDM4 | O15151 | 2/20 | 0.54 |
| ▸ | TP53 | P04637 | 2/20 | 0.54 |
| ▸ | TLR2 | O60603 | 2/20 | 0.50 |
| ▸ | CASP3 | P42574 | 1/20 | 0.50 |
| ▸ | IDO1 | P14902 | 1/20 | 0.49 |
| ▸ | SYK | P43405 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4599025 | 1.00 | MDM2 (0.54) | MDM2MDM4TP53TLR2CASP3 | |
| SCHEMBL29382463 | 1.00 | MDM2 (0.54) | MDM2MDM4TP53TLR2CASP3 | |
| SCHEMBL29687581 | 1.00 | MDM2 (0.54) | MDM2MDM4TP53TLR2CASP3 | |
| SCHEMBL29484085 | 1.00 | MDM2 (0.54) | MDM2MDM4TP53TLR2CASP3 | |
| SCHEMBL30645711 | 1.00 | MDM2 (0.54) | MDM2MDM4TP53TLR2CASP3 | |
| SCHEMBL38664164 | 1.00 | MDM2 (0.54) | MDM2MDM4TP53TLR2CASP3 | |
| SCHEMBL12757436 | 1.00 | MDM2 (0.54) | MDM2MDM4TP53TLR2CASP3 | |
| SCHEMBL4600320 | 1.00 | MDM2 (0.54) | MDM2MDM4TP53TLR2CASP3 | |
| Water SCHEMBL29698763 | 0.99 | MDM2 (0.53) | MDM2MDM4TP53TLR2CASP3 | |
| SCHEMBL1000225 | 0.96 | MDM2 (0.52) | MDM2MDM4TP53TLR2CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12616761-B2 | CXCR4-targeting compounds | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2026-05-05 | — | — | US | disclosed |
| EP-4725957-A1 | GROUP OF CYCLIC ALKALINE LIPOPEPTIDE COMPOUNDS, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences (CN) | 2026-04-15 | — | — | EP | disclosed |
| EP-4660303-A2 | PCSK9 ANTAGONIST COMPOUNDS | Merck Sharp & Dohme LLC (US) | 2025-12-10 | — | — | EP | disclosed |
| US-20250313579-A1 | LIGAND COMPOUNDS COMPRISING A CHELATING GROUP AS A BRIDGING GROUP | Technische Universität München (DE) | 2025-10-09 | — | — | US | disclosed |
| EP-3810626-B1 | PCSK9 ANTAGONIST COMPOUNDS | MERCK SHARP & DOHME LLC (US) | 2025-07-23 | — | — | EP | disclosed |
| US-20250206781-A1 | PCSK9 ANTAGONIST COMPOUNDS | MERCK SHARP & DOHME LLC (US) | 2025-06-26 | — | — | US | disclosed |
| CN-114874293-B | Cyclic polypeptide compound and preparation method and application thereof | 中国医学科学院医药生物技术研究所 | 2025-05-23 | — | — | CN | disclosed |
| US-20250129125-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2025-04-24 | — | — | US | disclosed |
| US-12209145-B2 | PCSK9 antagonist compounds | MERCK SHARP & DOHME LLC (US) | 2025-01-28 | — | — | US | disclosed |
| EP-4291250-B1 | DUAL MODE RADIOTRACER AND THERAPEUTICS | UNIV MUENCHEN TECH (DE) | 2025-01-15 | — | — | EP | disclosed |
| US-11427616-B2 | PCSK9 antagonist compounds | MERCK SHARP & DOHME LLC (US) | 2022-08-30 | — | — | US | disclosed |
| WO-2022171901-A1 | DUAL MODE RADIOTRACER AND THERAPEUTICS | Technische Universität München (DE) | 2022-08-18 | — | — | WO | disclosed |
| US-11413352-B2 | Conjugate based systems for controlled insulin delivery | Merck, Sharp & Dohme LLC (US) | 2022-08-16 | — | — | US | disclosed |
| CN-114874293-A | Cyclic polypeptide compounds and preparation method and application thereof | 中国医学科学院医药生物技术研究所 | 2022-08-09 | — | — | CN | disclosed |
| US-11332499-B2 | Cyclic peptides and methods of use thereof | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2022-05-17 | — | — | US | disclosed |
| WO-2022082312-A1 | NOVEL CXCR4-TARGETING COMPOUNDS | PROVINCIAL HEALTH SERVICES AUTHORITY (CA) | 2022-04-28 | — | — | WO | disclosed |
| US-11306125-B2 | PCSK9 antagonists bicyclo-compounds | MERCK SHARP & DOHME CORP. (US) | 2022-04-19 | — | — | US | disclosed |
| US-20220106361-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2022-04-07 | — | — | US | disclosed |
| WO-2022050529-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | ㈜베르티스 | 2022-03-10 | — | — | WO | disclosed |
| US-20220041674-A1 | THERAPEUTIC AND DIAGNOSTIC AGENTS FOR CANCER | Technische Universität München (DE) | 2022-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220106361-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | PAICS, CYCS, LSS | MDM2 685/4885MDM4 1699/4885TP53 732/4885 |
| US-11332499-B2 | Cyclic peptides and methods of use thereof | ANPEP, NPR3, XPNPEP1 | MDM2 4364/4885MDM4 2240/4885TP53 2148/4885 |
| US-20250129125-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | PAICS, CYCS, LSS | MDM2 685/4885MDM4 1699/4885TP53 732/4885 |
| US-20220041674-A1 | THERAPEUTIC AND DIAGNOSTIC AGENTS FOR CANCER | CXCR4, CXCL12, CXCR3 | MDM2 3497/4885MDM4 974/4885TP53 214/4885 |
| US-11413352-B2 | Conjugate based systems for controlled insulin delivery | GPR119, INSR, IGF1R | MDM2 1195/4885MDM4 4832/4885TP53 4472/4885 |
| US-11306125-B2 | PCSK9 antagonists bicyclo-compounds | PCSK9, PCSK7, PCSK6 | MDM2 4586/4885MDM4 4847/4885TP53 4061/4885 |
| US-12616761-B2 | CXCR4-targeting compounds | CXCR4, CXCR2, CXCR3 | MDM2 3597/4885MDM4 3817/4885TP53 1733/4885 |
| US-11427616-B2 | PCSK9 antagonist compounds | PCSK9, PCSK7, PCSK6 | MDM2 4549/4885MDM4 4743/4885TP53 4401/4885 |
| US-12209145-B2 | PCSK9 antagonist compounds | PCSK9, PCSK7, PCSK6 | MDM2 4549/4885MDM4 4743/4885TP53 4401/4885 |
| US-20250313579-A1 | LIGAND COMPOUNDS COMPRISING A CHELATING GROUP AS A BRIDGING GROUP | SHBG, SLC40A1, TFRC | MDM2 3583/4885MDM4 1896/4885TP53 1168/4885 |
| US-20250206781-A1 | PCSK9 ANTAGONIST COMPOUNDS | PCSK9, PCSK7, PCSK6 | MDM2 4549/4885MDM4 4743/4885TP53 4401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.